Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris M Parry

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|February 3, 2016
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based TherapyJennifer Giandhari, Adriaan E Basson, Katherine Sutherland, et al.
AIDS Research and Human Retroviruses|October 11, 2012
HIV-1 subtype distribution trends and evidence of transmission clusters among incident cases in a rural clinical cohort in southwest Uganda, 2004-2010Anne Kapaata, Frederick Lyagoba, Deogratius Ssemwanga, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Isotopic Radiolabeling of the Antiretroviral Drug [<sup>18</sup>F]Dolutegravir for Pharmacokinetic PET ImagingMarion Tisseraud, Sébastien Goutal, Thomas Bonasera, et al.
Open Forum Infectious Diseases|March 26, 2025
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT TrialsCharlotte-Paige Rolle, José R Arribas, Roberto Ortiz, et al.
The Journal of General Virology|March 1, 2015
Analysis of the history and spread of HIV-1 in Uganda using phylodynamicsGonzalo Yebra, Manon Ragonnet-Cronin, Deogratius Ssemwanga, et al.
ACS Omega|October 14, 2024
Improved Automated Radiosynthesis of [<sup>18</sup>F]Dolutegravir: Toward Clinical ApplicationsSteve Huvelle, Antoine Pinon, Christine Coulon, et al.
Therapeutic Advances in Infectious Disease|March 27, 2025
Fostemsavir resistance in clinical context: a narrative reviewJonathan M Schapiro, Rolf Kaiser, Mark Krystal, et al.
Plos One|August 30, 2014
Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort studyAndrew Swale, Fabio Miyajima, Paul Roberts, et al.
AIDS Research and Human Retroviruses|May 9, 2015
Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase InhibitorsJonathan K Kayondo, Nicaise Ndembi, Chris M Parry, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1Adele L McCormick, Chris M Parry, Anne Crombe, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|February 3, 2016
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based TherapyJennifer Giandhari, Adriaan E Basson, Katherine Sutherland, et al.
AIDS Research and Human Retroviruses|October 11, 2012
HIV-1 subtype distribution trends and evidence of transmission clusters among incident cases in a rural clinical cohort in southwest Uganda, 2004-2010Anne Kapaata, Frederick Lyagoba, Deogratius Ssemwanga, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Isotopic Radiolabeling of the Antiretroviral Drug [<sup>18</sup>F]Dolutegravir for Pharmacokinetic PET ImagingMarion Tisseraud, Sébastien Goutal, Thomas Bonasera, et al.
Open Forum Infectious Diseases|March 26, 2025
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT TrialsCharlotte-Paige Rolle, José R Arribas, Roberto Ortiz, et al.
The Journal of General Virology|March 1, 2015
Analysis of the history and spread of HIV-1 in Uganda using phylodynamicsGonzalo Yebra, Manon Ragonnet-Cronin, Deogratius Ssemwanga, et al.
ACS Omega|October 14, 2024
Improved Automated Radiosynthesis of [<sup>18</sup>F]Dolutegravir: Toward Clinical ApplicationsSteve Huvelle, Antoine Pinon, Christine Coulon, et al.
Therapeutic Advances in Infectious Disease|March 27, 2025
Fostemsavir resistance in clinical context: a narrative reviewJonathan M Schapiro, Rolf Kaiser, Mark Krystal, et al.
Plos One|August 30, 2014
Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort studyAndrew Swale, Fabio Miyajima, Paul Roberts, et al.
AIDS Research and Human Retroviruses|May 9, 2015
Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase InhibitorsJonathan K Kayondo, Nicaise Ndembi, Chris M Parry, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1Adele L McCormick, Chris M Parry, Anne Crombe, et al.
Pageof 4